Related Experiment Video

Updated: Oct 25, 2025

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.5K

Targeting c-MET to Enhance the Efficacy of Olaparib in Prostate Cancer

Zhenwei Wang1,2, Zhihong Dai1, Bingwei Wang2

  • 1Department of Urinary Surgery, Second Hospital of Dalian Medical University, Dalian, Liaoning, People's Republic of China.

Oncotargets and Therapy
|August 11, 2021
PubMed
Abstract

Insights

Combining c-MET and PARP inhibitors like PHA665752 and olaparib shows promise for treating prostate cancer. This dual approach effectively inhibits cancer cell growth and DNA repair, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Therapeutics

Background:

  • Prostate cancer is a leading cause of male cancer deaths globally.
  • Olaparib (a PARP inhibitor) is approved for prostate cancer but has limitations due to cytotoxicity and off-target effects.
  • New strategies are needed to enhance olaparib's efficacy in prostate cancer treatment.

Purpose of the Study:

  • To investigate novel therapeutic strategies for improving olaparib efficacy in prostate cancer.
  • To evaluate the combined effects of c-MET inhibition and PARP inhibition on prostate cancer cell lines.
  • To assess the impact of combined inhibition on DNA damage response and repair mechanisms.

Main Methods:

  • Prostate cancer cell lines were treated with PHA665752 (c-MET inhibitor) and/or olaparib (PARP inhibitor).
  • Cytotoxicity, colony formation, and cell invasion/migration were assessed using cell counting kit-8, colony formation assays, and transwell assays.
  • DNA damage, homologous repair, and RAD51 translocation were analyzed via Western blotting, immunofluorescence, and comet assays.

Main Results:

  • Combined c-MET and PARP inhibition synergistically blocked prostate cancer cell growth.
  • Invasion and migration of cancer cells were significantly suppressed by the combination therapy.
  • Dual inhibition impaired DNA damage response and homologous repair by downregulating RAD51 nuclear translocation.

Conclusions:

  • The combination of PHA665752 (c-MET inhibitor) and olaparib (PARP inhibitor) presents a promising therapeutic strategy for prostate cancer.
  • This combination enhances anti-cancer effects by disrupting DNA repair pathways.
  • Further investigation into this combined approach may lead to improved treatment outcomes for prostate cancer patients.
Keywords:
PARP inhibitorPHA665752combination therapyprostate cancer

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.4K
Evaluating In Vitro DNA Damage Using Comet Assay10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.4K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.3K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.2K